Talk:Nancy Thornberry
This article must adhere to the biographies of living persons (BLP) policy, even if it is not a biography, because it contains material about living persons. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libellous. If such material is repeatedly inserted, or if you have other concerns, please report the issue to this noticeboard.If you are a subject of this article, or acting on behalf of one, and you need help, please see this help page. |
![]() | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||||||||||||||||||
|
Edits to Nancy Thornberry wiki for accuracy and currency
editI am a paid consultant to the company for which Ms. Thornberry works, as disclosed on my talk page, and I have been trying to make changes to her page to bring it up to date. I have read the various rules on wikipedia for making edits as a paid consultant and none of the proposed edits are contentious or libelous; they are all accurate facts. The changes requested are as follows, and can also be seen in their entirety as carefully written in previous edits to the page that have since been reversed:
Introduction Ms. Thornberry is no longer the CEO of Kallyope, Inc. She is the founding CEO. She now holds the position Chair, Research & Development and is a member of the company's board of directors. [1]
Career Subsequent to joining the boards of Intarcia Therapeutics and Abide Therapeutics, she joined the boards of directors of Schrodinger Therapeutics (2019) [2] and Denali Therapeutics (2021).[3]
The change above also applies to the last sentence in her Research section.
Additionally, she is no longer on the boards of Intarcia Therapeutics or Abide Therapeutics. I do not have a citation for this but it is a fact and is not contentious or libelous.
In the section Research there is a paragraph describing her work at her present employer, Kallyope. I wish to update this for accuracy to the following:
At Kallyope Inc., drug discovery focuses on the study of the hormonal and neural communication between the gut and the brain to better understand and improve health and nutrition.Cite error: A <ref>
tag is missing the closing </ref>
(see the help page).
The final paragraph,, as mentioned above, should be changed to:
Thornberry is currently on the boards of directors of Kallyope Inc, Schrodinger Therapeutics, which employs computational biology for the identification of small molecules therapeutics, and Denali Therapeutics, a biotechnology company focused on neurodegeneration.
Please let me know if I have requested these changes incorrectly or if there is anything else I can do to help implement them. Thank you.
Ephraim Gursky (talk) 14:48, 13 May 2022 (UTC)Ephraim Gursky
References
- ^ https://finance.yahoo.com/news/kallyope-announces-ceo-transition-company-120000033.html
- ^ https://www.biospace.com/article/releases/schrodinger-appoints-drug-discovery-veteran-nancy-thornberry-to-board-of-directors/
- ^ https://finance.yahoo.com/news/denali-therapeutics-announces-appointment-nancy-133000846.html